- Home
- SNTI vs ARMP Comparison
SNTI vs ARMP Comparison
Compare SNTI & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- ARMP
- Stock Information
- Founded
- SNTI 2016
- ARMP N/A
- Country
- SNTI United States
- ARMP United States
- Employees
- SNTI N/A
- ARMP N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SNTI Health Care
- ARMP Health Care
- Exchange
- SNTI Nasdaq
- ARMP Nasdaq
- Market Cap
- SNTI 50.3M
- ARMP 52.1M
- IPO Year
- SNTI N/A
- ARMP N/A
- Fundamental
- Price
- SNTI $1.70
- ARMP $2.45
- Analyst Decision
- SNTI Strong Buy
- ARMP Strong Buy
- Analyst Count
- SNTI 2
- ARMP 1
- Target Price
- SNTI $8.50
- ARMP $9.00
- AVG Volume (30 Days)
- SNTI 511.1K
- ARMP 13.9K
- Earning Date
- SNTI 08-12-2025
- ARMP 08-12-2025
- Dividend Yield
- SNTI N/A
- ARMP N/A
- EPS Growth
- SNTI N/A
- ARMP N/A
- EPS
- SNTI N/A
- ARMP N/A
- Revenue
- SNTI N/A
- ARMP $4,699,000.00
- Revenue This Year
- SNTI N/A
- ARMP $8.43
- Revenue Next Year
- SNTI $150.00
- ARMP N/A
- P/E Ratio
- SNTI N/A
- ARMP N/A
- Revenue Growth
- SNTI N/A
- ARMP 14.24
- 52 Week Low
- SNTI $1.52
- ARMP $0.90
- 52 Week High
- SNTI $16.94
- ARMP $4.45
- Technical
- Relative Strength Index (RSI)
- SNTI 29.96
- ARMP 61.30
- Support Level
- SNTI $1.86
- ARMP $2.14
- Resistance Level
- SNTI $2.12
- ARMP $2.61
- Average True Range (ATR)
- SNTI 0.15
- ARMP 0.15
- MACD
- SNTI 0.00
- ARMP -0.01
- Stochastic Oscillator
- SNTI 0.00
- ARMP 65.96
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.